Trinity Biotech plc announced the appointment of Mr. Aris Kekedjian as CEO with effect from October 3, 2022. He succeeds Mr. Ronan O'Caoimh, co-founder of Trinity Biotech, who will remain on the Trinity Biotech plc Board of Directors to advise the Company going forward. In addition, Mr. Kekedjian has also assumed the role of Chairman of the Board of Directors of Trinity Biotech plc.

Mr. Kekedjian' s appointment as CEO of Trinity Biotech coincides with what Trinity Biotech believes is a period of fundamental transformation in the diagnostic landscape. The Company expects that increasing utilisation of digital health and virtual care, along with the changes in consumer behaviour brought about by COVID-19, will drive a move to increased decentralised diagnostic testing – an area in which Trinity Biotech has held a leading position for over 20 years. Over the past two years Trinity Biotech has been repositioning itself to capitalise on this change, with a goal of building a world-class executive team driven to scale solutions in this evolving, digitising and interconnected diagnostic ecosystem.

Mr. Kekedjian's appointment introduces a proven global business leader to complement a number of recent senior executive hires from leading global companies.